Müller D - Search Results

1

Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry.

Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Schuchardt C, et al. Among authors: muller d. J Nucl Med. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. J Nucl Med. 2022. PMID: 34887335 Free PMC article.

2

Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.

Wehrmann C, Senftleben S, Zachert C, Müller D, Baum RP. Wehrmann C, et al. Among authors: muller d. Cancer Biother Radiopharm. 2007 Jun;22(3):406-16. doi: 10.1089/cbr.2006.325. Cancer Biother Radiopharm. 2007. PMID: 17651048

3

Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules.

Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J. Baum RP, et al. Among authors: muller d. J Nucl Med. 2010 Jun;51(6):892-7. doi: 10.2967/jnumed.109.073239. Epub 2010 May 19. J Nucl Med. 2010. PMID: 20484419 Free article.

4

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Zhang J, Kulkarni HR, Singh A, Niepsch K, Müller D, Baum RP. Zhang J, et al. Among authors: muller d. J Nucl Med. 2019 Mar;60(3):377-385. doi: 10.2967/jnumed.118.215848. Epub 2018 Aug 16. J Nucl Med. 2019. PMID: 30115686 Free article.

5

First-in-Humans Application of ¹⁶¹Tb: A Feasibility Study Using ¹⁶¹Tb-DOTATOC.

Baum RP, Singh A, Kulkarni HR, Bernhardt P, Rydén T, Schuchardt C, Gracheva N, Grundler PV, Köster U, Müller D, Pröhl M, Zeevaart JR, Schibli R, van der Meulen NP, Müller C. Baum RP, et al. Among authors: muller c, muller d. J Nucl Med. 2021 Oct;62(10):1391-1397. doi: 10.2967/jnumed.120.258376. Epub 2021 Feb 5. J Nucl Med. 2021. PMID: 33547209 Free PMC article.

6

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Baum RP, Zhang J, Schuchardt C, Müller D, Mäcke H. Baum RP, et al. Among authors: muller d. J Nucl Med. 2021 Nov;62(11):1571-1581. doi: 10.2967/jnumed.120.258889. Epub 2021 Mar 5. J Nucl Med. 2021. PMID: 33674401 Free PMC article.

7

The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.

Schuchardt C, Kulkarni HR, Prasad V, Zachert C, Müller D, Baum RP. Schuchardt C, et al. Among authors: muller d. Recent Results Cancer Res. 2013;194:519-36. doi: 10.1007/978-3-642-27994-2_30. Recent Results Cancer Res. 2013. PMID: 22918780

8

First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.

Baum RP, Kulkarni HR, Müller D, Satz S, Danthi N, Kim YS, Brechbiel MW. Baum RP, et al. Among authors: muller d. Cancer Biother Radiopharm. 2015 May;30(4):152-9. doi: 10.1089/cbr.2014.1747. Cancer Biother Radiopharm. 2015. PMID: 25945808 Free PMC article.

9

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with ¹⁵²Tb-DOTATOC.

Baum RP, Singh A, Benešová M, Vermeulen C, Gnesin S, Köster U, Johnston K, Müller D, Senftleben S, Kulkarni HR, Türler A, Schibli R, Prior JO, van der Meulen NP, Müller C. Baum RP, et al. Among authors: muller c, muller d. Dalton Trans. 2017 Oct 31;46(42):14638-14646. doi: 10.1039/c7dt01936j. Dalton Trans. 2017. PMID: 28825750

10

Preclinical investigations and first-in-human application of ¹⁵²Tb-PSMA-617 for PET/CT imaging of prostate cancer.

Müller C, Singh A, Umbricht CA, Kulkarni HR, Johnston K, Benešová M, Senftleben S, Müller D, Vermeulen C, Schibli R, Köster U, van der Meulen NP, Baum RP. Müller C, et al. Among authors: muller d. EJNMMI Res. 2019 Jul 25;9(1):68. doi: 10.1186/s13550-019-0538-1. EJNMMI Res. 2019. PMID: 31346796 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,888 results

Search Page